Pfizer's chairman and CEO, Albert Bourla, stated regarding the acquisition of Seagen and its focus on oncology, "Seagen acquisition and oncology.
It is what it is - our new Covid.
I think will be blockbuster drugs... they will have significant impact on cancer patients."